Diseases of the central nervous system, which once occupied a large component pharmaceutical industry research and development portfolio, have for many years played smaller part in major pharma pipelines—primarily due to well cited challenges target validation, valid translational models, clinical trial design. Unfortunately, this decline interest has occurred tandem with an increase medical ne...